| Bid | 0.89 |
| Market Cap | 36.92M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.57 |
| PE Ratio (ttm) | -0.57 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.99 |
| Volume | 38,724 |
| Avg. Volume (20D) | 92,600 |
| Open | 0.91 |
| Previous Close | 0.92 |
| Day's Range | 0.89 - 0.92 |
| 52-Week Range | 0.84 - 3.46 |
| Beta | undefined |
About RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclona...
Analyst Forecast
According to 6 analyst ratings, the average rating for RLYB stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 798.88% from the latest price.
1 month ago · businesswire.com
Rallybio to Present at the 2024 Evercore ISI HealthCONx ConferenceNEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...
1 month ago · businesswire.com
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...